These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 32611737)

  • 1. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
    Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
    BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn's disease.
    Ong C; Lim PT; Logarajah V; Liwanag MJ; Ang BX; Cher Y; Chiou FK; Kader A
    BMC Gastroenterol; 2018 Dec; 18(1):185. PubMed ID: 30541458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
    Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T;
    J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
    Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
    Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study.
    Uhlen S; Belbouab R; Narebski K; Goulet O; Schmitz J; Cézard JP; Turck D; Ruemmele FM
    Inflamm Bowel Dis; 2006 Nov; 12(11):1053-7. PubMed ID: 17075346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
    van Linschoten RCA; Jansen FM; Pauwels RWM; Smits LJT; Atsma F; Kievit W; de Jong DJ; de Vries AC; Boekema PJ; West RL; Bodelier AGL; Gisbertz IAM; Wolfhagen FHJ; Römkens TEH; Lutgens MWMD; van Bodegraven AA; Oldenburg B; Pierik MJ; Russel MGVM; de Boer NK; Mallant-Hent RC; Ter Borg PCJ; van der Meulen-de Jong AE; Jansen JM; Jansen SV; Tan ACITL; van der Woude CJ; Hoentjen F;
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):343-355. PubMed ID: 36736339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].
    Hisamatsu T; Matsumoto T; Watanabe K; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    J Crohns Colitis; 2019 Sep; 13(9):1097-1104. PubMed ID: 30753377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
    Dassopoulos T; Sultan S; Falck-Ytter YT; Inadomi JM; Hanauer SB
    Gastroenterology; 2013 Dec; 145(6):1464-78.e1-5. PubMed ID: 24267475
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
    Jongsma MME; Vuijk SA; Cozijnsen MA; van Pieterson M; Norbruis OF; Groeneweg M; Wolters VM; van Wering HM; Hojsak I; Kolho KL; van Wijk MP; Teklenburg-Roord STA; de Meij TGJ; Escher JC; de Ridder L
    Eur J Pediatr; 2022 Aug; 181(8):3055-3065. PubMed ID: 35672586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn's disease.
    Zhou S; Huang Z; Hou W; Lin Y; Yu J
    Inflamm Res; 2024 Feb; 73(2):199-209. PubMed ID: 38168701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine use of thiopurines in maintaining remission in pediatric Crohn's disease.
    Boyle BM; Kappelman MD; Colletti RB; Baldassano RN; Milov DE; Crandall WV
    World J Gastroenterol; 2014 Jul; 20(27):9185-90. PubMed ID: 25083093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate for maintaining remission in paediatric Crohn's patients with prior failure or intolerance to thiopurines: a multicenter cohort study.
    Haisma SM; Lijftogt T; Kindermann A; Damen G; de Ridder L; Escher JC; Mearin ML; de Meij T; Hendriks D; George E; Hummel T; Norbruis O; van Rheenen P
    J Crohns Colitis; 2015 Apr; 9(4):305-11. PubMed ID: 25656249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate for induction of remission in refractory Crohn's disease.
    Alfadhli AA; McDonald JW; Feagan BG
    Cochrane Database Syst Rev; 2005 Jan; (1):CD003459. PubMed ID: 15674908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
    Matsumoto T; Motoya S; Watanabe K; Hisamatsu T; Nakase H; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    J Crohns Colitis; 2016 Nov; 10(11):1259-1266. PubMed ID: 27566367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azathioprine: state of the art in inflammatory bowel disease.
    Sandborn WJ
    Scand J Gastroenterol Suppl; 1998; 225():92-9. PubMed ID: 9515759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
    Ruemmele FM; Veres G; Kolho KL; Griffiths A; Levine A; Escher JC; Amil Dias J; Barabino A; Braegger CP; Bronsky J; Buderus S; Martín-de-Carpi J; De Ridder L; Fagerberg UL; Hugot JP; Kierkus J; Kolacek S; Koletzko S; Lionetti P; Miele E; Navas López VM; Paerregaard A; Russell RK; Serban DE; Shaoul R; Van Rheenen P; Veereman G; Weiss B; Wilson D; Dignass A; Eliakim A; Winter H; Turner D; ;
    J Crohns Colitis; 2014 Oct; 8(10):1179-207. PubMed ID: 24909831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.